These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 10155313)

  • 81. Lenograstim: an update of its pharmacological properties and use in chemotherapy-induced neutropenia and related clinical settings.
    Dunn CJ; Goa KL
    Drugs; 2000 Mar; 59(3):681-717. PubMed ID: 10776839
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
    Frampton JE; Yarker YE; Goa KL
    Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Economic analysis of lenograstim in the correction of neutropenia following chemotherapy for non-Hodgkin's lymphoma.
    Souêtre E; Qing W
    Pharmacoeconomics; 1994; 6 Suppl 2():36-43. PubMed ID: 10172484
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Economic evaluation of lenograstim for prophylaxis of chemotherapy-induced neutropenia in patients with small cell lung cancer.
    Drummond M; Davies L
    Pharmacoeconomics; 1994; 6 Suppl 2():44-52. PubMed ID: 10155594
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia.
    Bradstock K; Matthews J; Young G; Lowenthal R; Baxter H; Arthur C; Bashford J; Brighton T; Cannell P; Dunlop L; Durrant S; Enno A; Eliadis P; Gill D; Gillett A; Gottlieb D; Januszewicz H; Joshua D; Leahy M; Schwarer A; Taylor K;
    Leukemia; 2001 Sep; 15(9):1331-8. PubMed ID: 11516093
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation.
    Gisselbrecht C; Prentice HG; Bacigalupo A; Biron P; Milpied N; Rubie H; Cunningham D; Legros M; Pico JL; Linch DC
    Lancet; 1994 Mar; 343(8899):696-700. PubMed ID: 7510813
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression.
    Antman KS; Griffin JD; Elias A; Socinski MA; Ryan L; Cannistra SA; Oette D; Whitley M; Frei E; Schnipper LE
    N Engl J Med; 1988 Sep; 319(10):593-8. PubMed ID: 3045544
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Bone marrow transplantation in the treatment of patients with lymphoma.
    Armitage JO
    Blood; 1989 May; 73(7):1749-58. PubMed ID: 2653463
    [No Abstract]   [Full Text] [Related]  

  • 89. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation.
    Sheridan WP; Morstyn G; Wolf M; Dodds A; Lusk J; Maher D; Layton JE; Green MD; Souza L; Fox RM
    Lancet; 1989 Oct; 2(8668):891-5. PubMed ID: 2477656
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin's lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial.
    Lazarus HM; Andersen J; Chen MG; Variakojis D; Mansour EG; Oette D; Arce CA; Oken MM; Gerson SL
    Blood; 1991 Aug; 78(3):830-7. PubMed ID: 1859894
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission.
    Dufoir T; Saux MC; Terraza B; Marit G; Guessard S; Foulon G; Reiffers J
    Bone Marrow Transplant; 1992 Oct; 10(4):323-9. PubMed ID: 1422487
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Effect of lenograstim on the cost of autologous bone marrow transplantation. A preliminary communication.
    Brice P; Godin S; Libert O; Marolleau JP; Makki J; Extra JM; Faure P; Gisselbrecht C
    Pharmacoeconomics; 1995 Mar; 7(3):238-41. PubMed ID: 10155313
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Overview of the lenograstim pharmacoeconomics programme.
    Oster G; Menzin J; Richard D; Cour-Chabernaud V
    Pharmacoeconomics; 1994; 6 Suppl 2():9-17. PubMed ID: 10155596
    [TBL] [Abstract][Full Text] [Related]  

  • 94.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 95.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 96.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 97.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 98.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 99.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 100.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.